In support of a multipolar biopharma world: Guest Commentary

While participating in a recent PhRMA Forum panel on “China’s leading edge: what’s at risk,” I was struck by how quickly the conversation slides into a zero-sum frame: The U.S. leads only if China is contained. Coming from outside both the U.S. and China, I see a different possibility: a multipolar biopharma world in which the U.S. continues to thrive even as China becomes meaningfully stronger.

Can we reconcile having a strong U.S. industry with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this implies some level of rebalancing away from the U.S.? Arguably, this is the most important question for the future of the global industry...